Sepsis-related outcomes of patients with Philadelphia-negative myeloproliferative neoplasms
Recommended Citation
Gonzalez-Mosquera LF, Moscoso B, Tobar P, et al. Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms [published correction appears in Cancer Invest. 2023 Apr 5;:1]. Cancer Invest. 2023;41(5):423-431. doi:10.1080/07357907.2023.2187059
Abstract
We analyzed the National Inpatient Sample (NIS) database to study the sepsis-related outcomes in patients with Philadelphia negative myeloproliferative neoplasms (MPN). A total of 82,087 patients were included, most had essential thrombocytosis (83.7%), followed by polycythemia vera (13.7%), and primary myelofibrosis (2.6%). Sepsis was diagnosed in 15,789 (19.2%) patients and their mortality rate was higher than nonseptic patients (7.5% vs 1.8%; p < .001). Sepsis was the most significant risk factor of mortality (aOR, 3.84; 95% CI, 3.51-4.21), others included liver disease (aOR, 2.42; 95% CI, 2.11-2.78), pulmonary embolism (aOR, 2.26; 95% CI, 1.83-2.80), cerebrovascular disease (aOR, 2.05; 95% CI, 1.81-2.33), and myocardial infarction (aOR, 1.73; 95% CI, 1.52-1.96).
Correction in:
- Correction. Cancer Invest. 2023;41(5):I. doi:10.1080/07357907.2023.2197388
Document Type
Article
PubMed ID
36883674
Affiliations
Advocate Illinois Masonic Medical Center